Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 3975-3984

  Pal, Manojit ^a   Madan, Manjula ^a   Padakanti, Srinivas ^a   Pattabiraman, Vijaya R ^a   Kalleda, Srinivas ^a   Vanguri, Akhila ^a   Mullangi, Ramesh ^a   Mamidi, N V S Rao ^a   Casturi, Seshagiri R ^a   Malde, Alpeshkumar ^a   Gopalakrishnan, B ^a   Yeleswarapu, Koteswar R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO 4 [5 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H 1 PYRAZOLYL] 1 BENZENESULFONAMIDE; 3 FLUORO 4 [5 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H 1 PYRAZOLYL] 1 BENZENESULFONAMIDE; 3 FLUORO 4 [5 (4 METHYLSULFANYLPHENYL) 3 TRIFLUOROMETHYL 1H 1 PYRAZOLYL] 1 BENZENESULFONAMIDE; ANTIINFLAMMATORY AGENT; BENZENESULFONAMIDE DERIVATIVE; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FLUORINE; INDOMETACIN; KETOROLAC; PARECOXIB; PRODRUG; PYRAZOLE DERIVATIVE; ROFECOXIB; SODIUM; SODIUM N1 PROPIONYL 3 FLUORO 4 [5 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H 1 PYRAZOLYL] 1 BENZENESULFONAMIDE; UNCLASSIFIED DRUG; VALDECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; MALE; MOLECULAR MODEL; NONHUMAN; PAIN; PAW EDEMA; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SEMINAL VESICLE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EDEMA; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, WISTAR; SHEEP; SODIUM; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0141790770     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020563g     Document Type: Article

References (37)

1. Xie, W.; Chipman, J. G.; Roberson, D. L.; Erickson, R. L.; Simmons, D. L. Expression of a Mitogen-Responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing Proc. Natl. Acad. Sci. 1991, 88, 2692-2696.
2. (a) Allison, M. C.; Howatson, A. G.; Torrance, C. J.; Lee, F. D.; Russell, R. I. G. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1992, 327, 749-754.
3. (b) Wallace, J. L. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal antiinflammatory drugs (NSAIDs). Am. J. Med. 1999, 107 (6A), 11S-17S.
4. DeWitt, D. L.; Smith, W. L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 1412-1416.
5. Gans, K. R.; Galbraith, W. K.; Roman, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewes, W. E Antiinflammatory and safety profile of DUP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. 1990, 254, 180-187.
6. Futuki, N.; Takahashi, S.; Yokoyama, M.; Arai, I.; Higuchi, S.; Otomo, S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47, 55-59.
7. (a) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doctor, S.; Granto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. M.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib) J. Med. Chem. 1997, 40, 1347-1365.
8. (b) Talley, J. J.; Penning, T. D.; Collins, P. W.; Rogier, D. J., Jr.; Malecha, J. W.; Miyashiro, J. M.; Bertenshaw, S. R.; Khanna, I. K.; Graneto, M. J.; Rogers, R. S.; Carter, J. S.; Docter, S. H.; Yu, S. S. US Patent Application US 5760068 A, 2 Jun 1998; Chem. Abstr. 1998, 129, 54367.
9. (c) Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Henichart, J.-P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 779-782.
10. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Either, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O Neil, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′ -methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Bioorg Med. Chem. Lett. 1999, 9, 1773-1778.
11. Pasinetti, G. M. Cyclooxygenase and Inflammation in Alzheimer's Disease: Experimental Approaches and Clinical Intervention. J. Neurosci. Res. 1998, 54, 1-6.
12. (a) Subbaramaiah, K.; Zakim, D.; Weksler, B. B.; Dannenberg, A. J. Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention. Proc. Soc. Exp. Biol. Med. 1997, 216, 201-210.
13. (b) BenEzra, D. Ocular inflammation: Basic and clinical concepts; Martin Dunitz: London, 1999; 523 pp (ISBN: 1853175072).
14. Niemi, T. T.; Backman, J. T.; Syrjala, M. T. Ketorolac reduces postoperative narcotic requirements. Acta Anaesthesiol. Scand. 2000, 44, 69-74.
15. (a) Talley, J. J.; Bertenshaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboltd, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]-sulfonyl] propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J. Med. Chem. 2000, 43, 1661-1663.
16. (b) Talley, J. J.; Malecha, J. W.; Bertenshaw, S.; Graneto, M. J.; Carter, J.; Li, J.; Nagarajan, S.; Brown, D. L.; Rogier, D. J., Jr.; Penning, T. D.; Khanna, I. K.; Xu, X.; Weier, R. M. US Patent Application US 5932598, 3 Aug 1999.
17. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 2001, 286, 954-959.
18. (a) Pattabiraman, V. R.; Padakanti, S.; Veeramaneni, V. R.; Pal, M.; Yeleswarapu, K. R.; Synthesis of 3,4-diaryl substituted maleic anhydride/maleimide via unusual oxidative cyclization of phenacyl ester/amide. Synlett 2002, 6, 947-951.
19. (b) Padakanti, S.; Veeramaneni, V. R.; Pattabiraman, V. R.; Pal, M.; Yeleswarapu, K. R. A Simple and Rapid Entry to 5-Alkyl (Aryl)-5-Hydroxy-3,4-Diarylfuranones and 3a-Hydroxy-1-Aryl-2,3a,4,5-Tetrahydronaphthofuranones via a Tandem Esterification and Oxidative Cyclization Process. Tetrahedron Lett. 2002, 43, 8715-8719.
20. (c) Pal, M.; Rao, V. V.; Srinivas, P.; Murali, N.; Akhila, V.; Premkumar M.; Rao, C. S.; Misra, P.; Ramesh M.; Rao Y. K. Synthesis and cyclooxygenase (COX-1/COX-2) inhibiting property of 3,4-diarylfuranones. Indian J. Chem. 2003, 42B, 593-601.
21. (d) Pal, M.; Batchu, V. R.; Khanna, S.; Yeleswarapu, K. R. Regioselective aluminium chloride induced heteroarylation of pyrrolo[1,2-b]pyridazines: Its scope and application. Tetrahedron 2002, 58, 9933-9940.
22. Introduction of a second substituent on the phenylsufonamide moiety has been reported recently. For example, in the case of oxazole, see; (a) Hashimoto, H.; Imamura, K.; Haruta, J.-I.; Wakitani, K. 4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: Enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522 J. Med. Chem. 2002, 45, 1511-1517.
23. For pyrazole see; (b) Lohray, V. B.; Singh, S. K.; Venkateswarlu, A.; Lohray, B. B.; Ganapathi, R. P.; Rajagopalan, R.; Misra, P. World Patent Application WO 20000/66562, 9 Nov 2000; Chem. Abstr. 2000, 133, 335232.
24. (c) Brown, D. L.; Graneto, M. J.; Ludwig, C. L.; Talley, J. J. World Patent Application WO 2001081332 A2, 1 Nov 2001; Chem. Abstr. 2001, 135, 344477.
25. For furanone see (d) Pal, M.; Rao, Y. K.; Rajagopalan, R.; Misra, P.; Kumar, P. M.; Rao, C. S. World Patent Application WO 01/90097, 29 Nov 2001; Chem. Abstr. 2002, 136, 5893.
26. (a) Filyakova, V. I.; Karpenko, N. S.; Kuznetsova, O. A.; Pashkevich, K. I. New fluorinated synthons: Lithium salts derived from fluorinated β-diketones. Russ. J. Org. Chem. 1969, 34, 381-387.
27. (b) Singh, S. P.; Kumar, D.; Batra, H.; Rozas, I.; Elguero, J. The reaction between hydrazines and β-dicarbonyl compounds: Proposal for a mechanism. Can. J. Chem. 2000, 78, 1109-1120.
28. (c) Sloop, J. C.; Bumgardner, C. L.; Loehle, W. D. J. Fluorine Chem. 2002, 118, 135-148.
29. Brideau, C.; Kargman, S.; Liu, S.; Dallob, A. L.; Ehrich, E. W.; Rodger, I. W.; Chan, C.-C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 1996, 45, 68-74.
30. Chan, C.-C.; Boyce, S.; Brideau, C.; Ford-Hutchinson, A. W.; Gordon R.; Guoy, D.; Hill, R.; Li, C.-S.; Mancini, J.; Penneton, M.; Prasit, P.; Rasori, R.; Riendeau, D.; Roy, P.; Targari, P.; Vickers, P.; Wong, E.; Rodger, I. W. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach J. Pharmacol. Exp. Ther. 1995, 274, 1531-1537.
31. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 1996, 384, 644-648.
32. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesh, C.; Browner, M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct. Biol. 1996, 3, 927-933.
33. Hemler, H.; Lands, W. E. M.; Smith, W. L. Purification of the cyclooxygenase that forms prostagladins. Demonstration of two forms of iron in the holoenzyme. J. Biol. Chem. 1976, 251, 5575-5579.
34. Cromlish, W. A.; Payette, P.; Culp, S. A.; Ouellet, M.; Percival, M. D.; Kennedy, B. P. High-level expression of active human cyclooxygenase-2 in insect cells. Archives of Biochemistry and Biophysics 1994, 314, 193-199.
35. Copeland, R. A.; Williams, J. M.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzaskos, J. M. Mechanism of Selective Inhibition of the Inducible Isoform of Prostaglandin G/H Synthase Proc. Natl. Acad. Sci USA 1994, 91, 11202-11206.
36. SYBYL 6.8. Molecular Modelling Software, Tripos Associates Inc., 1699 South Hanley Road, St. Louis, MO 63144.
37. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.